| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Enrollment reduced: 403 -> 167 participants |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Trial sites reduced: 51 -> 46 locations |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
Trial terminated |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Primary completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-11 | NCT05083481 A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab… |
date change Completion moved earlier: 2026-06-30 -> 2026-05-11 |
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Recruitment opened |
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Trial sites expanded: 0 -> 9 locations |
| 2026-06-09 | NCT07566156 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… |
Trial sites expanded: 1 -> 9 locations |
| 2026-06-09 | NCT06997497 A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… |
Trial sites expanded: 192 -> 196 locations |
| 2026-06-06 | NCT06901531 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… |
Trial sites expanded: 238 -> 246 locations |
| 2026-06-06 | NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
date change Primary completion pushed: 2026-03 -> 2027-09 |
| 2026-06-06 | NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
date change Completion pushed: 2026-03 -> 2027-09 |
| 2026-06-06 | NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… |
Trial sites expanded: 241 -> 247 locations |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Primary completion moved earlier: 2029-02-02 -> 2028-04-23 |
| 2026-06-06 | NCT05355701 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced… |
date change Completion moved earlier: 2030-08-06 -> 2029-10-25 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Primary completion pushed: 2026-04-03 -> 2027-12-31 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Completion pushed: 2029-07-27 -> 2030-07-03 |
| 2026-06-03 | NCT07456852 Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in… |
Recruitment opened |
| 2026-06-03 | NCT07456852 Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in… |
date change Primary completion pushed: 2028-03-31 -> 2028-04-30 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07619313 AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07621497 FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Phase 3 | Recruiting |
| 2026-05-26 | NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | Psoriasis | Not Yet Recruiting |
| Phase 3 | |||
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma | Recruiting |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients… | Muscle Invasive Bladder Urothelial Carcinoma | Recruiting |
| NCT03801876 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Recruiting |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced… | Advanced Esophageal Adenocarcinoma | Recruiting |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab… | HER2-positive Gastric Cancer | Recruiting |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or… | Locally Advanced Pancreatic Adenocarcinoma | Recruiting |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… | Gastric Cancer | Recruiting |
| NCT07043400 | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… | Metastatic Gastric Adenocarcinoma | Recruiting |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of… | Metastatic Colorectal Carcinoma | Recruiting |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… | Pancreatic Cancer | Recruiting |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… | Pancreatic Cancer | Recruiting |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… | Colorectal Neoplasms | Recruiting |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… | Colorectal Neoplasms | Recruiting |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… | Colorectal Neoplasms | Recruiting |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Recruiting |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… | Colon Adenocarcinoma | Recruiting |
| NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… | Urothelial Cancer | Recruiting |
| NCT04340141 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable… | Pancreatic Adenosquamous Carcinoma | Active, Not Recruiting |
| NCT04094688 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or… | Colorectal Adenocarcinoma | Active, Not Recruiting |
| NCT00433420 | Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating… | Breast Cancer | Active, Not Recruiting |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy… | Urinary Bladder Neoplasms | Active, Not Recruiting |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | PRETEXT I Hepatoblastoma | Active, Not Recruiting |
| NCT03504397 | A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Active, Not Recruiting |
| NCT04248452 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients… | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Active, Not Recruiting |